NUCLEOLIN and cancer: More promising alternatives to AS1411 include versions with modified nucleobases or backbones (such as AT11, AT11-L0, and AT11-B0) or with modifications at the terminus of sequences (such as AS1411-N6) [12,13] to be used as promising drug delivery platforms due to their safety profile, ability to induce durable responses, and higher drug accumulation in some cancer cells [8,9] due to NCL targeting [14].